Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astri Therapeutics Inc (NQ: ATXS )

9.650 +0.310 (+3.32%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Astri Therapeutics Inc

< Previous 1 2 3 4 5 Next >
Moderna To Rally Over 42%? Here Are 10 Other Price Target Changes For Monday
Morgan Stanley cut VTEX (NYSE: VTEX) price target from $7 to $5.  Morgan Stanley analyst Cesar Medina downgraded the stock from Overweight to Equal-Weight. VTEX shares fell 4.9% to close at $3.52 on... 
Via Benzinga
Dow Dips Over 800 Points; S&P 500 Down 2.8%
U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping more than 800 points. 
Via Benzinga
Why Third Harmonic Bio Shares Are Trading Lower By Over 78%? Here Are 40 Stocks Moving In Thursday's Mid-Day Session
Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) jumped 69.6% to $0.2604 after gaining 17% on Wednesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share. 
Via Benzinga
RCI Hospitality, AbCellera Biologics And Some Other Big Stocks Moving Higher On Thursday
U.S. stocks traded lower, with the Dow Jones dropping over 600 points on Thursday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Astria Therapeutics' Potential Hereditary Angioedema Candidate Shows Encouraging Action In Healthy Participants
Via Benzinga
Astria Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Announces Positive Preliminary Results from the Phase 1a Clinical Trial of STAR-0215 in Healthy Subjects
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics to Present STAR-0215 Modeling and Simulation Data at the 2022 American College of Allergy, Asthma and Immunology Annual Meeting
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics to Host Virtual R&D Day: Update on STAR-0215 and Its Clinical Development
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics to Present at Upcoming Investment Conferences
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update
From Astria Therapeutics, Inc.
Via Business Wire
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
The European Commission (EC) has approved AstraZeneca (NASDAQ: AZN) and Merck’s (NYSE: MRK) LYNPARZA as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients... 
Via Benzinga
Astria Therapeutics Commences Initial-Stage Skin Disorder Study, Sees Preliminary Data By Year-end
Astria Therapeutics (NASDAQ: ATXS) announced initiation of a Phase 1a clinical trial of STAR-0215 in healthy subjects. STAR-0215 is designed to provide long-acting, effective attack prevention for... 
Via Benzinga
Astria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0215, a Monoclonal Antibody Inhibitor of Plasma Kallikrein for Treatment of Hereditary Angioedema
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics to Present at Upcoming Wedbush PacGrow Healthcare Conference 2022
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
Recap Of Thursday's Biotech Catalysts - End of The Day Summary
Via Benzinga
Astria Therapeutics Gets FDA Nod For Initial-Stage Hereditary Angioedema Study
The U.S. Food and Drug Administration (FDA) announced clearance to Astria Therapeutics’ (NASDAQ: ATXS) Investigational New Drug (IND) application for STAR-0215 in the treatment of Hereditary Angioedema... 
Via Benzinga
Daily Biotech Pulse: GSK's Kidney Disease Drug Approved For Children, Tonix Pharma To Launch Monkeypox Vaccine Study In Kenya, Positive Effect Of Cyclerion's Schizophrenia Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Astria Therapeutics Announces FDA Clearance of IND Application for STAR-0215, a Monoclonal Antibody Inhibitor of Plasma Kallikrein for Treatment of Hereditary Angioedema
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Names Chris Morabito Chief Medical Officer
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics to Participate in Virtual Fireside Chat at Upcoming H.C. Wainwright 1st Annual Hereditary Angioedema Conference
From Astria Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Passage Bio (NASDAQ:PASG) shares moved upwards by 7.7% to $2.66 during Friday's after-market session. The market value of their outstanding shares is at $144.4 million. 
Via Benzinga
Astria Therapeutics Presents New Preclinical Data Showing Differentiated Profile of STAR-0215, in Development for Treatment of Hereditary Angioedema
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics to Present New Preclinical STAR-0215 Data at the European Academy of Allergy and Clinical Immunology 2022 Hybrid Congress
From Astria Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.